Floatz logo

Pioglitazone

Polycystic Ovary Syndrome

Beni-Suef UniversitySmall moleculePhase 4 / ApprovedActive
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Polycystic Ovary Syndrome cohort.

View all 50

Same molecule, other indications

Pioglitazone is also rated in:

diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative ·
75 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →